These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22771885)

  • 21. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.
    Li Z; Bonekamp S; Halappa VG; Corona-Villalobos CP; Pawlik T; Bhagat N; Reyes D; Lai H; Geschwind JF; Kamel IR
    Radiology; 2012 Jul; 264(1):97-109. PubMed ID: 22627602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical imaging features of primary central nervous system lymphoma that mimics glioblastoma: utility of intravoxel incoherent motion MR imaging.
    Suh CH; Kim HS; Lee SS; Kim N; Yoon HM; Choi CG; Kim SJ
    Radiology; 2014 Aug; 272(2):504-13. PubMed ID: 24697149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.
    Sunwoo L; Choi SH; Yoo RE; Kang KM; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Park SW; Sohn CH; Won JK; Park SH; Kim IH
    Neuroradiology; 2015 Nov; 57(11):1111-20. PubMed ID: 26232204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of grade and subtype of meningiomas by using histogram analysis of diffusion-tensor imaging metrics.
    Wang S; Kim S; Zhang Y; Wang L; Lee EB; Syre P; Poptani H; Melhem ER; Lee JY
    Radiology; 2012 Feb; 262(2):584-92. PubMed ID: 22084207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.
    Law M; Oh S; Babb JS; Wang E; Inglese M; Zagzag D; Knopp EA; Johnson G
    Radiology; 2006 Feb; 238(2):658-67. PubMed ID: 16396838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
    Gasparetto EL; Pawlak MA; Patel SH; Huse J; Woo JH; Krejza J; Rosenfeld MR; O'Rourke DM; Lustig R; Melhem ER; Wolf RL
    Radiology; 2009 Mar; 250(3):887-96. PubMed ID: 19244052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps.
    Emblem KE; Nedregaard B; Nome T; Due-Tonnessen P; Hald JK; Scheie D; Borota OC; Cvancarova M; Bjornerud A
    Radiology; 2008 Jun; 247(3):808-17. PubMed ID: 18487536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T.
    Dong Y; Liu Q
    J Comput Assist Tomogr; 2012; 36(4):361-6. PubMed ID: 22805661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging.
    Yabuuchi H; Hatakenaka M; Takayama K; Matsuo Y; Sunami S; Kamitani T; Jinnouchi M; Sakai S; Nakanishi Y; Honda H
    Radiology; 2011 Nov; 261(2):598-604. PubMed ID: 21852569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of dynamic contrast-enhanced perfusion with diffusion tensor imaging metrics in assessment of corticospinal tract infiltration in malignant glioma.
    Awasthi R; Verma SK; Haris M; Singh A; Behari S; Jaiswal AK; Rajput D; Pandey R; Rathore RK; Pandey CM; Gupta RK
    J Comput Assist Tomogr; 2010 Jan; 34(1):82-8. PubMed ID: 20118727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perfusion Computed Tomography (PCT) adopting different perfusion metrics: recurrence of brain metastasis or radiation necrosis?
    Vidiri A; Guerrisi A; Pinzi V; Fabi A; Mirri MA; Pompili A; Caporale N; Pace A; Crecco M; Marzi S
    Eur J Radiol; 2012 Jun; 81(6):1246-52. PubMed ID: 21458183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
    Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ
    Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parametric histogram analysis of dynamic contrast-enhanced MRI in multiple myeloma: a technique to evaluate angiogenic response to therapy?
    Zechmann CM; Traine L; Meissner T; Wagner-Gund B; Giesel FL; Goldschmidt H; Delorme S; Hillengass J
    Acad Radiol; 2012 Jan; 19(1):100-8. PubMed ID: 22142682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head and neck squamous cell carcinoma: diagnostic performance of diffusion-weighted MR imaging for the prediction of treatment response.
    King AD; Chow KK; Yu KH; Mo FK; Yeung DK; Yuan J; Bhatia KS; Vlantis AC; Ahuja AT
    Radiology; 2013 Feb; 266(2):531-8. PubMed ID: 23151830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance.
    De Cecco CN; Ganeshan B; Ciolina M; Rengo M; Meinel FG; Musio D; De Felice F; Raffetto N; Tombolini V; Laghi A
    Invest Radiol; 2015 Apr; 50(4):239-45. PubMed ID: 25501017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.